• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝达喹啉和德拉马尼在耐多药结核病患儿中的应用:何为 QTc 延长?

Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?

机构信息

From the Pediatric TB Clinic, Department of Pediatric Infectious Diseases, B J Wadia Hospital for Children, Mumbai, India.

出版信息

Pediatr Infect Dis J. 2020 Jun;39(6):512-513. doi: 10.1097/INF.0000000000002601.

DOI:10.1097/INF.0000000000002601
PMID:32032176
Abstract

Bedaquiline and delamanid used to treat extensively drug-resistant tuberculosis are known to cause prolonged QTc. Two children with extensively drug-resistant tuberculosis were put on bedaquiline and delamanid and had prolonged QTc on the Bazett formula but normal QTc by the Fridericia formula. Both had no adverse effects. Correct formula for monitoring QTc should be used thereby preventing unnecessary withholding of medicines.

摘要

贝达喹啉和德拉马尼过去被用于治疗广泛耐药结核病,已知会导致 QT 间期延长。两名患有广泛耐药结核病的儿童服用了贝达喹啉和德拉马尼,Bazett 公式显示 QT 间期延长,但 Fridericia 公式显示 QT 间期正常。两人均无不良反应。应使用正确的公式监测 QT 间期,从而避免不必要地停药。

相似文献

1
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?贝达喹啉和德拉马尼在耐多药结核病患儿中的应用:何为 QTc 延长?
Pediatr Infect Dis J. 2020 Jun;39(6):512-513. doi: 10.1097/INF.0000000000002601.
2
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.贝达喹啉和德拉马尼联合治疗 5 例广泛耐药肺结核患者。
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
3
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.德拉马尼与贝达喹啉联合用于治疗耐多药和广泛耐药结核病:一项系统评价
Int J Mol Sci. 2017 Feb 7;18(2):341. doi: 10.3390/ijms18020341.
4
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.亚美尼亚、印度和南非采用贝达喹啉与德拉马尼联合治疗耐多药结核病患者的早期安全性和疗效:一项回顾性队列研究。
Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13.
5
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.在耐多药结核病治疗期间低水平地奈达胺和贝达喹啉耐药的出现。
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.
6
Bedaquiline plus delamanid for XDR tuberculosis.贝达喹啉联合地拉马尼治疗广泛耐药结核病
Lancet Infect Dis. 2016 Mar;16(3):294. doi: 10.1016/S1473-3099(16)00047-5.
7
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.首例广泛耐药结核病使用德拉马尼和贝达喹啉治疗。
Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10.
8
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.贝达喹啉、德拉马尼或两者联合治疗利福平耐药结核病患者的 QT 影响:一项 2 期、开放标签、随机、对照试验。
Lancet Infect Dis. 2021 Jul;21(7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12.
9
Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.贝达喹啉单药方案与贝达喹啉联合德拉马尼方案治疗耐多药结核病患者的疗效和安全性比较:印度尼西亚苏托莫综合学术医院的实施情况。
Int J Mycobacteriol. 2024 Apr 1;13(2):140-146. doi: 10.4103/ijmy.ijmy_88_24. Epub 2024 Jun 15.
10
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.广泛耐药结核病的个体化管理:诊断、治疗及生物标志物
Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. doi: 10.1080/14787210.2017.1247692. Epub 2016 Oct 24.

引用本文的文献

1
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.新药贝达喹啉和德拉马尼在儿童耐多药结核病治疗中的进展。
Front Cell Infect Microbiol. 2023 Jun 13;13:1183597. doi: 10.3389/fcimb.2023.1183597. eCollection 2023.
2
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.含德拉马尼方案与耐多药结核病:系统评价和荟萃分析。
Int J Infect Dis. 2022 Nov;124 Suppl 1(Suppl 1):S90-S103. doi: 10.1016/j.ijid.2022.02.043. Epub 2022 Mar 2.
3
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
儿童耐多药和广泛耐药结核病的治疗:贝达喹啉和德拉马尼的作用
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.